There is emerging evidence that HIV increases the risk of serious events other than AIDS, such as cardiovascular, renal, and hepatic events and malignancies , and the incidence of these events appears higher than that of AIDS events at higher CD4+ cell counts [2,3].
Although several studies have examined the risk of death following different AIDS-related events [4–9], the risk of death following different serious non-AIDS (SNA) events in HIV-infected persons has not been studied nor has the relative impact of AIDS and non-AIDS events in terms of subsequent mortality been reported. Such information would be useful for targeting specific interventions and for prioritizing future research.
We used data from two large international randomized clinical trials in HIV-infected patients with high CD4+ cell counts, the Strategies for Management of Anti-Retroviral Therapy (SMART) trial, and the Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT) to examine the risk of all-cause mortality after experiencing AIDS and SNA events. AIDS events were further categorized as serious and nonserious based on earlier work ; non-AIDS events were subdivided as cardiovascular, renal, hepatic, or malignancies. We hypothesized that the risk of death differed following AIDS versus non-AIDS events and that this risk also varied by type of AIDS and non-AIDS events.
The design, methods, and results of the SMART study have been published [10,11]. A total of 5472 participants with CD4+ cell count more than 350 cells/μl were randomized to either CD4+ cell count guided episodic use of antiretroviral therapy (ART) [Drug Conservation (DC) group] or to continuous use of ART [Viral Suppression (VS) group]. Median [interquartile range (IQR)] follow-up was 2.4 (1.8–3.5) years.
The design, methods, and results of ESPRIT have also been reported [12,13]. A total of 4111 participants with a CD4+ cell count 300 cells/μl or more were included in the analysis cohort and were randomized to interleukin-2 (IL-2) plus continuous ART or to continuous ART alone. Median (IQR) follow-up was 6.8 (5.7–7.6) years.
In both SMART and ESPRIT, local practice guidelines were consulted for use of preventive treatments for opportunistic diseases and for SNA conditions. Likewise, the treatment of these conditions was not directed by either protocol and was managed according to local clinical guidelines.
A medical history was obtained prior to randomization for participants in both SMART and ESPRIT. A history of AIDS events, hepatic events, and cardiovascular disease (CVD) events was collected in both studies. History of non-AIDS cancers and renal disease was only available for SMART participants. Due to the use of IL-2, inclusion and exclusion criteria were more restrictive in ESPRIT than in SMART with respect to past events. For example, in ESPRIT, patients were required to not have evidence of active clinical disease for at least 1 year for any AIDS condition. In addition, patients with malignancies who were taking cytoxic chemotherapy were not eligible.
AIDS events (henceforth called AIDS) were defined in SMART  and ESPRIT  according to the revised clinical case definition for AIDS published by the Centers for Disease Control and Prevention , as well as additional conditions related to immunodeficiency. Serious AIDS events that were prespecified in each protocol were progressive multifocal leukoencephalopathy, lymphoma, visceral Kaposi's sarcoma, AIDS dementia complex, toxoplasmosis, histoplasmosis, cryptococcosis, Mycobacterium avium complex disease, wasting syndrome, and cytomegalovirus disease .
SNA events included major CVD events: myocardial infarction (MI), stroke, or coronary artery disease (CAD) requiring an invasive procedure; end-stage renal disease (ESRD); decompensated cirrhosis; and all non-AIDS-defining malignancies, excluding nonmelanomatous skin cancers.
Multiple events of a given type were not included. AIDS and SNA events were considered if the participant survived at least 1 day after diagnosis. One fatal (survival <1 day) AIDS and 11 fatal non-AIDS events occurred and were not included in the AIDS and SNA event categories. For both studies, all AIDS and SNA events and deaths were reviewed by a Clinical Events Committee, blinded to treatment group. Underlying cause of death was classified using the system of the Coding of Death in HIV Project .
Cox proportional hazards models, stratified by study and treatment group, were used to examine predictors for AIDS and SNA events including the following covariates: age, sex, race, BMI, blood pressure medication, lipid-lowering medication, hepatitis co-infection, nadir CD4+ cell count, prior SNA, prior AIDS, and time-updated CD4+ cell count and HIV-RNA (≤500 versus >500 copies/ml).
Cox models for survival (with date of randomization as time zero) that included an indicator for the event of interest as a time-updated covariate were used to assess the effect of AIDS or SNA event on the risk of death. For example, when assessing the risk of an AIDS event on subsequent mortality, a variable representing AIDS took a value of 0 before the event and 1 thereafter for participants who experienced an AIDS event; participants who did not experience an AIDS event took a value of 0 throughout follow-up. These models were stratified by study and treatment group. Adjusted Cox models included age, sex, race, baseline CD4+ cell count, nadir CD4+ cell count, baseline HIV-RNA (≤500 versus >500 copies/ml), and time-updated CD4+ count and HIV-RNA (≤500 versus >500 copies/ml). To examine whether the risk of death following an AIDS or SNA event varied by study or treatment group within study, expanded Cox models were considered with interaction terms. To assess whether the increased risk of death for SNA versus AIDS varied by time period after the event, hazard ratios for death associated with SNA and AIDS were calculated for the first 6 months and for after 6 months following the diagnosis of the event by including time-updated covariates for the two periods. Selected analyses were also considered after excluding those with a history of AIDS or SNA at study entry.
Among those who experienced AIDS and SNA events, Kaplan–Meier estimates of the cumulative percentage dead at 6 and 12 months after AIDS and SNA events were determined. The time from the first AIDS and first SNA event until death was depicted using a Kaplan–Meier plot. Predictors of mortality following an event were examined using Cox models (with the date of the event as time zero) stratified by study and treatment group. Covariates considered for mortality following an AIDS event were age, sex, race, BMI, nadir CD4+ cell count, AIDS or non-AIDS event prior to study entry, and CD4+ cell count and HIV-RNA prior to nonfatal event. An additional multivariate model was assessed adding an indicator for whether or not the AIDS event met the serious definition. For mortality following an SNA event, baseline diabetes, hepatitis B or C co-infection, use of lipid-lowering medication and use of blood pressure medication were considered in addition to the covariates considered for AIDS. Smoking status was available for SMART participants but not for ESPRIT participants. Thus, an analysis examining predictors for mortality following SNA events for only SMART participants, including smoking status in addition to the covariates listed above, was also carried out.
Statistical analyses were performed using SAS, version 9.1 (Cary, North Carolina, USA). All reported P values are two-sided.
Role of the funding source
SMART and ESPRIT were funded by the National Institute of Allergy and Infections Disease. As members of the International Network for Strategic Initiative in Global HIV Trials Executive Committee, funding source staff participated in the review of the paper but were not part of the writing group.
Demographic and HIV disease characteristics
As previously reported [10,13], median CD4+ cell count levels at study entry for SMART and ESPRIT were 597 and 457, respectively. The percentage with HIV-RNA 500 or less was 72.6 for SMART and 79.7 for ESPRIT. Eighty-four percent of participants in SMART were on ART at study entry and all ESPRIT participants were required to be on or initiating ART at the time of randomization. Median time since first taking ART was 6.0 years for SMART and 4.2 years for ESPRIT.
Overall, 12% of participants had BMI levels of 30 kg/m2 or greater. Forty percent of SMART participants were current smokers and 42% had cholesterol levels of 200 or greater at study entry (these data were not collected in ESPRIT).
Table 1 shows baseline characteristics and latest CD4+ cell count and HIV-RNA levels by nonfatal event status. AIDS events occurred in 286 participants (158 in SMART and 128 in ESPRIT) at a rate of 0.7 per 100 person-years. SNA events occurred in 435 participants (205 in SMART and 230 in ESPRIT) at a rate of 1.0 per 100 person-years. Median (IQR) months from randomization to AIDS was 20 (8–32) for SMART and 36 (20–62) for ESPRIT for those who experienced an event. Median (IQR) months from randomization to SNA event was 17 (9–31) for SMART and 45 (23–65) for ESPRIT. Median (IQR) follow-up time following AIDS and SNA events was 17 (7–28) months for SMART and 31 (11–57) months for ESPRIT. Independent predictors for AIDS events included older age (P = 0.0007), history of AIDS (P < 0.0001), lower latest CD4+ cell count (P < 0.0001), and latest HIV-RNA more than 500 (P < 0.0001). Independent predictors associated with SNA event included older age (P < 0.0001), male sex (P = 0.0006), use of blood pressure medication (P = 0.009), use of lipid-lowering medication (P = 0.02), nadir CD4+ cell count (P = 0.05), history of SNA (P = 0.03), and latest HIV-RNA more than 500 (P = 0.03).
Twenty-eight percent of participants experiencing an AIDS event had latest CD4+ cell count levels lower than 250 cells/μl compared with 9% for those with an SNA event. Median (IQR) days from latest CD4+ cell count to event was 43 (20–77) for AIDS and 48 (22–74) for SNA. Participants who experienced an AIDS event, an SNA event and no event spent 12, 4, and 2% of follow-up time with CD4+ cell count levels less than 250 and 55, 76 and 76% of follow-up time with HIV-RNA levels less than or equal to 500, respectively.
Mortality associated with non-fatal AIDS and serious non-AIDS events
Overall, there were 167 deaths (rate = 1.1 per 100 person-years; 95% CI 0.9–1.3) in SMART and 223 deaths (rate = 0.8 per 100 person-years; 95% CI 0.7–0.9) in ESPRIT. In SMART, but not ESPRIT, death rates differed by treatment group. Rates were 1.4 (per 100 person-years; 95% CI 1.1–1.6) for the DC group and 0.8 (per 100 person-years; 95% CI 0.6–1.0) for the VS group.
Forty-seven participants (16%) who experienced AIDS and 115 participants (26%) who experienced SNA events subsequently died. In those who died, median (IQR) months from the event to death was 9 (6–21) for AIDS and 6 (2–19) for SNA. Twenty-six of the 47 deaths (55%) occurring after a nonfatal AIDS event were due to AIDS-related causes and 87 of the 115 deaths (76%) after a SNA event were due to SNA-related causes, including 60 cancer-related, 14 CVD-related, and 13 hepatic-related deaths. Twenty-five participants experienced both an AIDS and SNA event and are included in both event categories; eight of these participants died.
Six-month and 12-month cumulative mortality after experiencing an AIDS event were 4.7% (95% CI 2.8–8.0) and 11.1% (95% CI 7.9–15.7), respectively. These percentages were greater after experiencing an SNA event; 13.4% (95% CI 10.5–17.0) and 19.0% (95% CI 15.5–23.2) for 6-month and 12 month estimates (Table 2 and Fig. 1), respectively. Mortality following SNA events was highest for hepatic events, renal events, and malignancies with 12-month estimates of 39.7, 32.7, and 29.5%, respectively (Table 2). The most common non-AIDS malignancy was lung cancer for which 12-month mortality was 61.2%. The Kaplan–Meier plot (Fig. 1) shows a significantly higher risk of death following SNA events in comparison to the risk following AIDS events (log–rank 11.86; P = 0.0006).
The univariate hazard ratio for all-cause mortality for those who experienced an AIDS event versus those who did not was 7.4 (95% CI 5.4–10.1). The corresponding unadjusted hazard ratio for SNA events was 17.6 (95% CI 14.0–22.2). After adjusting for baseline covariates and latest CD4+ cell count and HIV-RNA, hazard ratios for death for those who experienced AIDS and SNA events were 4.9 (95% CI 3.6–6.8) and 11.4 (95% CI 9.0–14.5), respectively (P < 0.001 for difference in hazard ratios) (Fig. 2a and b). Results were consistent across studies and P values for tests for homogeneity across treatment groups for SMART, ESPRIT, and SMART/ESPRIT combined were 0.77, 0.57, and 0.93 for AIDS events and 0.49, 0.10, and 0.25 for SNA events, respectively. Risk of death was greater in the early follow-up period after SNA events. For example, in the first 2 months following an SNA event, the risk of death was 40.8 (95% CI 27.0–61.5). By 6 months, this hazard ratio was 27.6 (95% CI 20.3–37.5), and after 6 months, it was 7.1 (95% CI 5.3–9.6). The hazard ratios for death in the first 6 months following AIDS and afterwards were 5.8 (95% CI 3.3–10.2) and 4.6 (95% CI 3.2–6.7), respectively. During the first 6 months following a nonfatal event, the risk of death was significantly greater for SNA than for AIDS (P < 0.0001). This difference was not seen after the first 6 months (P = 0.49).
Adjusted hazard ratios for all-cause mortality associated with the different types of SNA events were 3.0 (95% CI 2.0–4.6) for CVD events, 16.8 (95% CI 7.3–38.7) for renal events, 19.5 (95% CI 11.4–33.4) for hepatic events, and 14.6 (95% CI 11.1–19.3) for non-AIDS malignancies (Fig. 3). The adjusted hazard ratio for death associated with lung cancer was 22.9 (95% CI 13.8–37.8). Risk of death also varied according to type of AIDS events. The adjusted hazard ratio for death following serious AIDS events was 10.8 (95% CI 7.3–16.1); for all other AIDS events, it was 3.1 (95% CI 2.0–4.7).
Results were similar when excluding participants with a history of AIDS or SNA events prior to randomization. When excluding participants with a history of an AIDS event, the adjusted hazard ratio for death associated with AIDS events during follow-up was 6.0 (95% CI 4.0–8.9). Similarly, when excluding participants with a history of an SNA event, the adjusted hazard ratios for death associated with SNA events during follow-up in SMART (patients with a history of CVD, non-AIDS cancer, cirrhosis, and ESRD excluded) and ESPRIT (patients with a history of CVD or cirrhosis excluded) were 15.4 (95% CI 10.1–23.3) and 11.3 (95% CI 8.1–15.8), respectively.
Predictors for mortality following AIDS or serious non-AIDS events
In a multivariate analysis, older age [hazard ratio per 10 years older = 1.4 (95% CI 1.0–1.9), P = 0.04] and lower CD4+ cell count prior to the nonfatal event [hazard ratio per 100 cells higher = 0.9 (95% CI 0.7–1.0), P = 0.04] were associated with death following an AIDS event. When adding an indicator for whether or not the AIDS event met the serious definition, age and latest CD4+ cell count remained significant and experiencing a serious AIDS event was associated with an increased risk of death [hazard ratio = 6.3 (95% CI 3.2–12.4), P < 0.0001]. Predictors associated with death following an SNA event were older age [hazard ratio per 10 years older = 1.4 (95% CI 1.1–1.8), P = 0.002], viral hepatitis (B and/or C) co-infection [hazard ratio = 2.0 (95% CI 1.2–3.3), P = 0.007], and diabetes [hazard ratio = 1.7 (95% CI 1.0–3.0), P = 0.05]. In an analysis of only SMART participants, smoking status was not a significant predictor of mortality following a SNA event [hazard ratio = 1.6 (95% CI 0.8–3.1), P = 0.14].
The number of participants who experienced SNA events in the SMART and ESPRIT studies exceeded those who experienced AIDS events by almost 50% (435 versus 286 events). As compared to participants who did not develop such an event, the risk of death following SNA events was twice as high compared with AIDS events. This difference in mortality risk for the different types of events was apparent early on and was maintained throughout the follow-up period.
This is consistent with other studies that have shown that, in the era of combination antiretroviral therapy, SNA events dominate morbidity at high CD4+ cell counts [2,16,17] and may even occur more frequently than AIDS events in individuals with advanced HIV . Additionally, the majority of deaths in HIV-infected persons are now due to non-AIDS causes [19–21]. In this study, the median CD4+ cell counts prior to AIDS and SNA events were 356 cells/ml (IQR 227–540) and 518 cells/ml (IQR 360–727), respectively.
As noted in other studies , we found that not all AIDS events were associated with the same risk of death. The hazard ratio for death following serious AIDS events, events which were associated with a higher risk of death before the availability of HAART , was 10.8 compared to 3.1 for all other AIDS events. Recent studies have reported that the risk of death following non-Hodgkin's lymphoma is particularly high [9,22]. In our study, 64% of the serious AIDS events were lymphomas (of any type), which resulted in a hazard ratio for death of 9.5.
SNA events were shown to be not only more frequent but also related to significantly higher mortality than AIDS events. Most of the SNA events in SMART and ESPRIT were CVD and cancer, with substantially fewer renal and hepatic events. Preventing SNA events in some patients may be clinically possible . Prevention of CVD is important, as it remains the most common SNA event and contributes significantly to all-cause mortality. Decreasing modifiable CVD risk factors could thus have an impact on mortality in HIV-infected individuals. Additionally, it has been shown that HIV-infected patients are as likely to achieve conventional risk factor treatment goals, such as normalizing blood pressure or lipid levels, as HIV-uninfected patients . The risk of death after experiencing a CVD event did not increase substantially after the first 6 months following the event. This is similar to reports in the general population in which the risk of death following CVD events was greatest in the early period after hospitalization with such an event [25,26].
Along with CVD, malignancies were the other most common type of SNA events in this analysis and contributed substantially to all-cause mortality. It has been shown that for some non-AIDS-defining malignancies there might be a benefit in routine screening . Despite this, HIV-infected patients are not always undergoing the same routine cancer screening tests as the general population . In addition, there are major risk factors, such as hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, tobacco smoking, or heavy alcohol consumption, which may contribute to specific non-AIDS malignances and can be addressed in clinical practice . In our study, lung cancer and prostate cancer were the most common cancers and mortality risk for these varied considerably, a finding consistent with data from the general population [25,26,30–32].
In our study, older age, diabetes, and co-infection with HBV or HCV were independent predictors for death following a non-AIDS event. This finding, along with prior information that patients with diabetes are at an increased risk of death following MI  and cancer  events in the general population, emphasizes the importance of identifying and properly managing patients with diabetes and other risk factors in order to prevent the occurrence of nonfatal events as well as to increase survival following these events. In contrast to the findings with AIDS events, latest CD4+ cell count was not an independent predictor for death following a non-AIDS event in our study. This may be due to the fact that these events occurred at higher CD4+ cell counts and that most of the follow-up time was spent at relatively high CD4+ cell counts.
Excluding participants with a history of nonfatal events at enrollment into SMART and ESPRIT did not change our results. Both studies enrolled relatively healthy participants with high CD4+ cell count levels and patients were not permitted to enroll in ESPRIT if there was any evidence of active clinical disease within the year prior to randomization. AIDS and SNA events experienced prior to enrollment most likely occurred long enough before enrollment into SMART and ESPRIT to allow participants to recover from the nonfatal event, attenuating the impact of any disease that occurred prior to enrollment.
The prevalence of risk factors, such as smoking, obesity, and elevated cholesterol levels, for the development of SNA events is high in our cohort and this has been noted in other HIV studies . A recent report found that mortality among patients who start ART, survive the first 6 months, and achieve an HIV-RNA level less than or equal to 500 copies/ml and CD4+ cell count 350 cells/μl or more is modestly higher than in the general population . The higher mortality may be due to these other risk factors. This highlights the importance of smoking cessation and the management of other modifiable risk factors.
There are some limitations to this study. We studied HIV-infected participants with higher CD4+ cell counts who met eligibility criteria for the randomized trials. Although both trials had broad inclusion criteria, participants who developed events may have been healthier than a random sample of HIV-infected participants. Another limitation was that smoking status was not collected in ESPRIT and hepatitis status and use of lipid-lowering and blood pressure-lowering drugs was not available for all ESPRIT participants.
In summary, by pooling results form two large studies in nearly 10 000 HIV-infected patients with carefully documented and adjudicated AIDS and SNA events, we have shown that the risk of death is greater following SNA than after AIDS events. This finding is important given the much greater frequency of SNA than that of AIDS events. Further, the risk of death varies by type of AIDS and SNA event. These results have implications for defining major outcomes in clinical studies and for setting priorities for the development and evaluation of interventions to reduce morbidity and mortality among patients infected with HIV.
The study was funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health [grant numbers U01AI042170 and U01AI46362 (SMART); U01AI46957 and U01AI068641 (ESPRIT)].
We would like to acknowledge the SMART and ESPRIT participants, the SMART study team (see  for list of investigators), the ESPRIT study team [ for list of investigators], and the INSIGHT Executive Committee.
Contribution of authors: J.N. performed statistical analyses and drafted the manuscript, B.A., J.D.K., A.L.R., and J.S. provided input into analyses and contributed to the interpretation of data and to writing the manuscript. D.W. supported statistical analyses and provided input into the analyses and interpretation of data. A.M. contributed to the development of the project, provided input into the analyses and interpretation of data, and contributed to writing the manuscript. All authors have approved the final version.
1. Phllips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22:2409–2418.
2. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Chiesi A, Gatell J, et al. Serious fatal and non fatal non-AIDS defining illnesses in Europe. Proceedings of the Conference on Retroviruses and Co-infection; San Francisco, California, USA; 2009.
3. Neaton JD, Grund B. Earlier initiation of antiretroviral therapy in treatment-naïve patients: implications of results of treatment interruption trials. Curr Opin HIV AIDS 2008; 3:112–117.
4. Neaton JD, Wentworth DN, Rhame F, Hogan C, Abrams DI, Deyton L. Considerations in choice of a clinical endpoint for AIDS clinical trials. Stat Med 2004; 13:2107–2125.
5. Lundgren JD, Pedersen C, Clumeck N, Gatell JM, Johnson AM, Ledergerber B, et al. Survival differences in European patients with AIDS, 1979–89. BMJ 1994; 308:1068–1073.
6. Mocroft AJ, Lundren JD, Monforte AD, Ledergerber B, Barton SE, Vella S, et al. Survival of AIDS patients according to type of AIDS-defining event. The AIDS In Europe Study Group. Int J Epidemiol 1997; 26:400–407.
7. Babiker AG, Darbyshire JH, Peto TEA, Walker S. Issues in the design and analysis of therapeutic trials in human immunodeficiency virus infection. J Royal Stat Soc 1998; 161:239–249.
8. Grabar S, Lanoy E, Allavena C, Mary-Krause M, Bentata M, Fischer P, et al. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med 2008; 9:246–256.
9. Antiretroviral Therapy Cohort Collaboration (ART-CC). Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 2009; 48:1138–1151.
10. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283–2296.
11. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy. A randomized trial. Ann Intern Med 2008; 149:289–299.
12. Emery S, Abrams DI, Cooper DA, Darbyshire JH, Lane HC, Lundgren JD, et al. The evaluation of subcutaneous proleukin (R) (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials 2002; 23:198–220.
13. The INSIGHT-ESPRIT Study Group and SILCAAT Scientific Committee. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361:1548–1559.
14. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1–19.
16. Reisler RB, Han C, Burman WJ, Tedaldi EM, Neaton JD. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr 2003; 34:379–386.
17. Bonnet F, Chene G, Thiebaut R, Dupon M, Lawson-Ayayi S, Pellegrin JL, et al. Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort 2000–2004. HIV Med 2007; 8:547–554.
18. Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, et al. Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. J Acquir Immune Defic Syndr 2009; 51:631–639.
19. Lau B, Gange S, Moore RD. Risk of non-AIDS related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007; 44:179–187.
20. Lifson AR, and the INSIGHT Cause of Death Writing Group. Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials 2008; 9:177–185.
21. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagloiola D, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The ‘Mortalite 2000 and 2005’ surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590–598.
22. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS 2009; 23:2029–2037.
23. Lundgren JD, Battegay M, Behrens G, De Wit S, Guaraldi G, Katlama C, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008; 9:72–81.
24. Adeyemi O, Vibhakar S, Max B. Are we meeting the American Diabetes Association goals for HIV-infected patients with diabetes mellitus? Clin Infect Dis 2009; 49:799–802.
25. Adabag AS, Therneau TM, Gersh BJ, Weston SA, Roger VL. Sudden death after myocardial infarction. JAMA 2008; 300:2022–2029.
26. Law MR, Watt HC, Wald NJ. The underlying risk of death after myocardial infarction in the absence of treatment. Arch Intern Med 2002; 162:2405–2410.
27. Phillips AA, Justman JE. Screening HIV-infected patients for non-AIDS-defining malignancies. Curr HIV/AIDS Rep 2009; 6:83–92.
28. Reinhold JP, Moon M, Tenner CT, Poles MA, Bini EJ. Colorectal cancer screening in HIV-infected patients 50 years of age and older: missed opportunities for prevention. Am J Gasteroenterol 2005; 100:1805–1812.
29. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123:187–194.
30. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310–1319.
31. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009; 59:225–249.
32. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced nonsmall-cell lung cancer. N Engl J Med 2002; 346:92–98.
33. Weitzman S, Wang C, Rosamond WD, Chambless LE, Cooper LS, Shahar E, Goff DC. Is diabetes an independent risk factor for mortality after myocardial infarction? The ARIC Surveillance Study. Acta Diabetol 2004; 41:77–83.
34. Barone BB, Hsin-Chieh Y, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus. JAMA 2008; 300:2754–2764.
35. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, Monforte A, et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179–1193.
36. The Antiretroviral Therapy Cohort Collaboration. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009; 38:1624–1633.
© 2010 Lippincott Williams & Wilkins, Inc.